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Activated protein C (APC) has potent anticoagulant and anti-
inflammatory properties that are mediated in part by its inter-
actions with its cofactor protein S and the endothelial cell pro-
tein C receptor (EPCR). The protein C/APC Gla domain is
implicated in both interactions. We sought to identify how the
protein C Gla domain enables specific protein-protein interac-
tions in addition to its conserved role in phospholipid binding.
The human prothrombin Gla domain, which cannot bind EPCR
or support proteinS cofactor activity, has 22/45 residues that are
not shared with the human protein C Gla domain. We hypoth-
esized that the unique proteinC/APCGla domain residueswere
responsible for mediating the specific interactions. To assess
this, we generated 13 recombinant protein C/APC variants
incorporating the prothrombin residue substitutions. Despite
anticoagulant activity similar towild-typeAPC in the absence of
protein S, APC variants APC(PT33–39) (N33S/V34S/D35T/
D36A/L38D/A39V) andAPC(PT36/38/39) (D36A/L38D/A39V)
were not stimulated by protein S, whereas APC(PT35/36)
(D35T/D36A) exhibited reduced protein S sensitivity. More-
over, PC(PT8/10) (L8V/H10K) displayed negligible EPCR affin-
ity, despite normal binding to anionic phospholipid vesicles and
factor Va proteolysis in the presence and absence of protein S. A
single residue variant, PC(PT8), also failed to bind EPCR. Factor
VIIa, which also possesses Leu-8, bound soluble EPCRwith sim-
ilar affinity towild-type proteinC, collectively confirmingLeu-8
as the critical residue for EPCR recognition. These results reveal
the specific Gla domain residues responsible for mediating pro-
tein C/APC molecular recognition with both its cofactor and
receptor and further illustrate the multifunctional potential of
Gla domains.
Protein C is the key component of the anticoagulant protein
C pathway (1, 2). Homozygous protein C deficiency is associ-
ated with severe neonatal thrombosis (3), whereas individuals
with heterozygous deficiency are thrombophilic (4). Protein C
is activated by the thrombin-thrombomodulin complex on
endothelial cells (5). Protein C activation is enhanced 5-fold
by protein C binding to the endothelial cell protein C receptor
(EPCR)2 (5). Activated protein C (APC) binds to anionic phos-
pholipid surfaces, where it inactivates procoagulant cofactors
factor Va (FVa) and factor VIIIa (FVIIIa), thereby attenuating
thrombin generation (6, 7). Proteolysis of FVa and FVIIIa by
APC is enhanced by the presence of theAPC cofactor, protein S
(8). APC also has potent anti-inflammatory (9–11) and anti-
apoptotic properties (12, 13), whichmay bemediated in part by
EPCR-bound APC activation of protease-activated receptor 1
(14).
Protein C is a vitamin K-dependent protein with a multido-
main structure comprising a serine protease domain, two epi-
dermal growth factor (EGF) domains, and a Gla domain (15).
Situated at the protein C N terminus, the Gla domain consists
of 45 amino acid residues. Of these, 9 glutamic acid (Glu) resi-
dues are post-translationally modified to -carboxyglutamic
acid (Gla) residues. Gla residues facilitate Ca2 ion coordina-
tion,which causes the domain to undergo a profound structural
transition (16). In this conformation, the protein C Ca2-
bound Gla domain binds to anionic phospholipids exposed on
the surface of activated endothelial cells and platelets, albeit
with lower affinity than other vitamin K-dependent proteins
(17–19).
The mechanism by which protein S exerts its cofactor activ-
ity on APC is not fully understood. Protein S enhances APC
affinity for phospholipids and is required for optimal alignment
of the APC active site for substrate cleavage (8, 20). Protein S
has also been reported to remove factor Xa (FXa) protection of
FVa in the prothrombinase complex (21). Several protein S
domains have been shown to contribute to APC cofactor activ-
ity, including the thrombin-sensitive region, EGF1, EGF2, and
the Gla domain (21–28). A direct role for the APC Gla domain
in mediating protein S cofactor activity was suggested by a
study in which a recombinant protein C chimera was generated
and the protein C Gla domain (residues 1–45) was replaced by
that of prothrombin (18). This chimera was resistant to protein
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of anAPC chimera inwhich theAPCGla domain residues 1–22
were substituted with the corresponding prothrombin residues
was enhanced by protein S, suggesting a role for APC residues
22–45. However, the precise residues responsible, present in
the protein C/APC Gla domain but not in prothrombin, were
not determined.
The protein C Gla domain is also required for EPCR binding
(29). A crystal structure of part of the protein C Gla domain
(residues 1–33) bound to soluble EPCR (sEPCR) indicated that
hydrophobic residues Phe-4 and Leu-8 contained within the
-loop of the protein C Gla domain and Gla residues 7, 25 and
29, bind EPCR (30). Despite the significant amino acid se-
quence conservation between the EPCR binding residues of the
protein C/APC Gla domain and that of other vitamin K-de-
pendent coagulation proteins, surprisingly only protein C/APC
has been reported to bind EPCR. Binding competition experi-
ments using FX, FXa, and protein S failed to prevent high affin-
ity protein C-EPCR binding (31). Consequently, the residues
that enable the EPCR to recognize and bind specifically to the
protein C/APC Gla domain are currently unknown.
In this study, we evaluated 13 protein C/APC recombinant
variants where protein C residues were substituted for those of
prothrombin at non-identical positions (22/45 Gla domain res-
idues). We assessed the binding of each variant for both phos-
pholipids and sEPCR and evaluated the APC variants in antico-
agulant activity assays in the presence and absence of protein S
in both purified protein and plasma systems. We describe the
critical residues in the APC Gla domain that mediate protein S
cofactor activity. Moreover, we have identified the protein C
Gla domain residue responsible for the specific “recognition” of
EPCR and how its presence in factor VII (FVII) also enables it to
bind EPCR.
EXPERIMENTAL PROCEDURES
Generation of Protein C Variants—The pRc/CMV vector
(Invitrogen) containing full-length proteinC cDNAwas used to
generate recombinant wild-type protein C and as a template for
PCR site-directed mutagenesis (QuikChange mutagenesis kit;
Stratagene) usingmutagenic oligonucleotide primers (available
on request) as before (32). Expression vectors for each proteinC
variant were used to transfect human embryonic kidney 293
cells (EuropeanCollection of Cell Cultures,Wiltshire, UK), and
G418-selected colonies expressing protein C at high levels were
picked for further expansion. Serum-free conditioned medium
containing each recombinant protein C was buffer exchanged
against 20 mM Tris-HCl, pH 7.4, 150 mM NaCl. Protein C was
purified by ion exchange chromatography using aQ-Sepharose
Fast Flow column (AmershamBiosciences) with a gradient elu-
tion using 20mMTris-HCl, pH 7.4, 150mMNaCl, 30mMCaCl2
as previously described (19, 33, 34). Protein C concentrations
were determined either by absorbance at 280 nmor by enzyme-
linked immunosorbent assay (32). The purity of all recombi-
nant proteins was confirmed by SDS-PAGE and Coomassie
staining, and Western blotting was performed using a horse-
radish peroxidase-conjugated polyclonal anti-protein C anti-
body (Dako, Ely, UK). To generate APC, wild-type protein C
and protein C variants were activated with Protac as previously
described (32). Kinetic values were used to active site titrate
each recombinant APC variant against wild-type APC.
Phospholipid Binding of Protein C Variants—A BIAcore X
system (BIAcore, Uppsala, Sweden) was used to evaluate pro-
tein C binding to anionic phospholipids. 10 g/ml of a Ca2-
dependent anti-protein C monoclonal antibody (Hematologic
Technologies Inc.) was immobilized onto both flow cells of a
CM5 sensor chip (BIAcore), corresponding to12,000 RU on
each flow cell. 50 l of wild-type or variant protein C was then
passed over the surface of one flow cell at a flow rate of 30
l/min until a response of 2,000 RU was achieved for each
protein C species tested. The flow cell with no protein C bound
was used to detect nonspecific binding. Phospholipids phos-
phatidylcholine/phosphatidylserine (PC/PS, 80%:20%) were
prepared as described previously (32) inHBS-N buffer (100mM
HEPES, pH 7.4, 150 mM NaCl) (BIAcore) containing 3 mM
CaCl2 and 0.6 mM MgCl2 and then passed over the surface of
the sensor chip at 30 l/min for 1 min. Phospholipids were
dissociated from the surface using 5l of 40mMoctyl glucoside
(Sigma) at the same flow rate. The maximum binding response
at each phospholipid concentration was assessed using BIA-
evaluation software (3.0) (BIAcore). The sensor chip surface
was regenerated using HBS-EP buffer (100 mMHEPES, pH 7.4,
150 mM NaCl, 3 mM EDTA, 0.005% v/v surfactant P20) (BIA-
core), for 5 min at 30 l/min.
EPCR Binding Affinity of Protein C Variants—Protein C
binding to sEPCR was quantitatively assessed as previously
described (32). Briefly, 300 ng of RCR-2 (a kind gift from K.
Fukudome, Saga Medical School, Japan; characterized in Ref.
32)was injected for 6min across both flow cells of aCM5 sensor
chip, generating a response of 8,000–9,000 RU. sEPCR was
expressed as described previously (32). sEPCR in HBS-P buffer
(100 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% v/v surfactant
p20) containing 3 mM CaCl2 and 0.6 mM MgCl2 was injected
and equilibrated. Protein C concentrations (12.5–200 nM) were
sequentially injected over both flow cells at a flow rate of 30
l/min for 80 s. The flow cell immobilized with RCR-2 without
sEPCR bound was used to detect nonspecific binding. Any
influence of mass transport effects was discounted from results
of binding and dissociation at different flow rates. HBS-EP
buffer (BIAcore) was used to dissociate the protein C-sEPCR
complex. The RCR-2 surface was regenerated with 10 mM gly-
cine-HCl, pH 2.5, after each set of experiments.
Determination of APC-mediated Factor Va Proteolysis—To
determine FVa degradation by APC, 0.32 nM APC was incu-
bated at 37 °Cwith phospholipid vesicles (PC/PS, 80%:20%) and
4 nM FVa (Hematologic Technologies Inc.) in 40 mM Tris-HCl,
140mMNaCl, 3mMCaCl2, and 0.3%w/v bovine serum albumin
(0.08 nM APC, 19 M phospholipids, and 1 nM FVa, final con-
centration). At specified time points over 20 min, 2-l aliquots
were removed and added to a prothrombinasemixture consist-
ing of 75 M phospholipids, 3 nM factor Xa, and 1.5 M pro-
thrombin (25 M phospholipids (PC/PS, 80%:20%), 1 nM factor
Xa, and 0.5 M prothrombin, final concentrations) (Hemato-
logic Technologies Inc.) for 3 min. Each reaction was then
stopped using 5 l of ice-cold 0.5 M EDTA. 100 l of the reac-
tionmixturewas removed and incubatedwith 50l of chromo-
genic substrate S-2238 (Chromogenix, Milan, Italy) to assess
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thrombin generation. The rate of S-2238 cleavage was meas-
ured at 405 nm using an iEMS plate reader MF (Labsystem,
Basingstoke, UK).
Protein S-enhanced Proteolysis of FVa by APC—Human pro-
tein S (2.5–25 nM) was incubated with 0.8 nM APC, 8 nM FVa,
and 75 M phospholipid vesicles (PC/PS/phosphatidylethanol-
amine (PE), 60%:20%:20%) in 40 mM Tris-HCl, pH 7.4, 140 mM
NaCl, 3 mM CaCl2, 0.3% (w/v) bovine serum albumin (0.2 nM
APC, 2 nM FVa, and 19 M phospholipid vesicles, final concen-
trations) for 2 min at 37 °C. A 2-l aliquot was added to 0.3 nM
FXa, 1.5M prothrombin, and 75M phospholipid vesicles (0.1
nM FXa, 0.5M prothrombin, and 25M phospholipid vesicles,
final concentrations) at 37 °C for 3min. 5l of ice-cold 250mM
EDTA stopped the reaction. 50 l of S-2238 was diluted 1:2
with 50mMTris-HCl, 150mMNaCl, pH 8.3, and added to 50l
of the reaction mixture. The rate of S-2238 cleavage was then
measured as before.
Protein S-dependent APC Anticoagulant Activity in Plasma—
Thrombin generation was assessed using a Fluoroskan Ascent
Plate Reader (Thermo Lab System, Helsinki, Finland) in com-
bination with Thrombinoscope software (SYNAPSE BV) as
previously described (35, 36). 80 l/well of protein C-deficient
plasma (Affinity Biologicals Inc., Ontario, Canada) was incu-
bated with 240 g/ml of anti-protein S polyclonal antibody or
the equivalent volumeofwater for 15min at room temperature.
Each plasma pool was then incubated with 16 pM recombinant
tissue factor (Dade Innovin, Dade Behring,Marburg, Germany)
and 17.5 M phospholipid vesicles (PC/PS/PE, 60%:20%:20%).
42 g/ml corn trypsin inhibitor (Hematologic Technologies
Inc.) was added to prevent contact activation. APC (3.5–7 nM)
was added to microtiter plate wells and the plasma mix with or
without anti-protein S polyclonal antibody subsequently
added, making a final volume of 100 l/well. Thrombin gener-
ation was initiated by automatic dispensation of 2.5 mM Z-Gly-
Gly-Arg-AMCHCl, 2.5% Me2SO, 18 mM HEPES, pH 7.4, 54
mg/ml bovine serum albumin, and 100 mM CaCl2 into each
well. Thrombin generation was quantitated using a thrombin
calibration standard (Synapse, Maastricht, Netherlands).
Measurements were taken at 20-s intervals for 40 min at wave-
lengths 390 nm (excitation) and 460 nm (emission).
RESULTS
Generation and Characterization
of Protein C Variants—To identify
protein C Gla domain residues
that enable protein S cofactor
activity and EPCR recognition, a
series of protein C variants with
prothrombin residue substitu-
tions at non-identical positions
were generated (Fig. 1). These
variants were divided into two
groups, those situated at the
N-terminal end of the protein C
Gla domain (residues 1–25) and
those located at the C-terminal
end incorporating the hydropho-
bic stack (residues 26–45). The
purity of each recombinant pro-
tein C variant was confirmed by Coomassie staining and
exhibited identical characteristic double bands under non-
reducing conditions upon Western blotting with an anti-
protein C polyclonal antibody (data not shown).
Phospholipid Binding of Protein CVariants—To characterize
theGla domain integrity of the recombinant protein C variants,
the ability of each variant to bind to phospholipidswas assessed.
Protein C was bound to the surface of a CM5 sensor chip by a
Ca2-dependent anti-protein C monoclonal antibody directed
against the heavy chain, and not the Gla domain-containing
light chain, of protein C. A protein C variant (E16D), possessing
a residue substitution that causes aberrant Ca2 binding and
Gla domain misfolding (32), was found to bind to the immobi-
lized antibody with equal affinity to human protein C, indicat-
ing that the antibody epitope was not on the Gla domain (data
not shown). Increasing concentrations of anionic phospholipid
vesicles were passed over the protein C surface and specific
bindingwas detected (Fig. 2A). Due to the slowdissociation rate
of the phospholipid-protein C interaction, thorough analysis of
the binding kinetics was not possible. The maximum binding
response at each phospholipid concentration was therefore
measured and used to qualitatively assess phospholipid bind-
ing. The binding response of both human protein C and recom-
binant wild-type protein C at each phospholipid concentration
tested was essentially identical (Fig. 2B). When the E16D pro-
tein C variant (which does not bind phospholipids) (32) was
immobilized, a minimal response to phospholipids was
detected (Fig. 2B, top panel), demonstrating the specificity of
this approach. The phospholipid binding of the remaining vari-
ants was found to be very similar to that of wild-type protein C
(Fig. 2B, middle and lower panels), with the exception of
PC(PT21/23/24) and PC(PT31–35). These variants exhibited
markedly reduced binding to phospholipids (Fig. 2B, middle
and lower panel, respectively), suggesting that these variants
most likely possess a misfolded Gla domain due to suboptimal
-carboxylation. The defective phospholipid binding of both
variants also resulted in severely impaired anticoagulant activ-
ity in protein C-deficient plasma (data not shown). Conse-
quently, these variants were not investigated further.
FIGURE 1. Amino acid sequence alignment of recombinant protein C Gla domain variants. The human
protein CGla domain (residues 1–45) shares 33% sequence identitywith the humanprothrombinGla domain.
13 protein C Gla domain variants were generated in which residues were substituted with the corresponding
human prothrombin Gla domain residues.
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Protein S-independent FVa Proteolysis by APC Variants—
Each protein C variant was activated by Protac, and the
amidolytic activity of each APC variant against a short chro-
mogenic substrate (S-2366) was tested and found to be iden-
tical to that of wild-type APC (data not shown). To deter-
mine whether the introduced prothrombin residue
substitutions influenced FVa pro-
teolysis in the absence of protein S,
each APC variant was investigated
for its ability to proteolyze FVa in
a phospholipid-dependent time
course reaction (Fig. 3). Under
these conditions, wild-type APC
reduced FVa cofactor activity to
21  5% after 20 min. APC vari-
ants were found to inactivate FVa
at effectively the same rate as wild-
type APC. Some variants exhibited
mildly increased FVa proteolysis,
including APC(PT11/12) (S11G/
S12N), APC(PT33–39) (N33S/
V34S/D35T/D36A/L38D/A39V),
and APC(PT35/36) (D35T/D36A)
(Fig. 3, A and B), possibly as a
result of the slightly increased
affinity for phospholipids of these
variants (Fig. 2).
Protein S Does Not Enhance
FVa Proteolysis by APC Variants
APC(PT33–39), APC(PT35/36),
and APC(PT36/38/39)—To exam-
ine the influence of substituted pro-
tein CGla domain residues inmedi-
ating protein S cofactor activity, the
ability of each APC variant to pro-
teolyze FVa in the presence of vary-
ing protein S concentrations was
determined. Wild-type APC re-
duced FVa cofactor activity to 27 8% of its original activity in
the presence of 25 nM protein S (Fig. 4). All N-terminal Gla
domain APC variants tested were stimulated by protein S nor-
mally (Fig. 4A), as were half of the C-terminal variants (Fig. 4B).
However, FVa proteolysis by APC variants APC(PT33–39) and
APC(PT36/38/39) (D36A/L38D/A39V) was not enhanced by
protein S. The remaining FVa activity in the presence of 25 nM
protein S with variants APC(PT33–39) and APC(PT36/38/39)
was 92 7 and 91 2%, respectively (Fig. 4B). TheAPC(PT35/
36) variant also exhibited a significantly impaired response to
protein S compared with wild-type APC, only reducing FVa
cofactor activity to 73 9% of its original value in the presence
of 25 nM protein S (Fig. 4B).
APC Variants Containing Residue Substitutions between
Positions 33–39 Are Not Enhanced by Protein S in Plasma—To
assess whether the observed reduced sensitivity to protein S
exhibited by APC variants APC(PT33–39), APC(PT36/38/39),
and APC(PT35/36) using purified plasma proteins was repli-
cated in the plasma milieu, an assay measuring tissue factor-
induced thrombin generation in protein C-deficient plasma
was used. Thrombin generation in protein C-deficient
plasma was initiated by the presence of tissue factor and
anionic phospholipid vesicles, generating an estimated
thrombin potential (ETP) of 1720  82 nM. When wild-type
APC was incubated in the protein C-deficient plasma, the
ETP diminished in a concentration-dependent manner (Fig.
FIGURE 2. Phospholipid binding to protein C variants. Recombinant protein C affinity for negatively
charged phospholipids (PC/PS, 80%:20%) was assessed by surface plasmon resonance (see “Experimental
Procedures”). A Ca2-dependent anti-protein C monoclonal antibody was immobilized onto both flow
cells of a CM5 sensor chip. Each protein C species was then bound to the second flow cell (2,000 RU), the
other flow cell acting as a “no protein C” control for nonspecific binding. A, increasing concentrations of
phospholipid vesicles (1.25–10 M) were passed over a wild-type protein C surface, and the maximum
binding responsewasmeasured. B, each of the protein C variants was tested in an identical manner to that
of wild-type protein C. Themaximum binding response (in RU) at each phospholipid concentration tested
was determined using BIAEvaluation software and plotted against phospholipid concentration. Top,
human plasma purified protein C, (Œ); wild-type protein C (f); protein C Gla domain variant E16D (dashed
line). Middle, wild-type protein C, (f); PC(PT3), (); PC(PT8/10), (); PC(PT11/12), (F); PC(PT18), ();
PC(PT21/23/24), (dashed line, ‚). Lower, wild-type protein C, (f); PC(PT28/30), (ƒ); PC(PT31–35), (dashed
line,); PC(PT33–39), (*); PC(PT35/36), (); PC(PT36/38/39), (E); and PC(PT42/44/45), ().
FIGURE 3. FVa proteolysis by recombinant APC variants. FVa (1 nM) was
incubated with APC (0.08 nM) in the presence of phospholipids (PC/PS, 80%:
20%; 19 M). At specified time points, an aliquot was removed and the FVa
cofactor activity determined using a prothrombinase assay (phospholipids
(25 M), FXa (1 nM), and prothrombin (0.5 M)) as described under “Experi-
mental Procedures.” Wild-type APC () in both panels. A, APC variants with
substitutions in theN-terminal half of theGladomain:APC(PT3), ();APC(PT8/
10), (E); APC(PT11/12),F; APC(PT18), (). B, APC variants with substitutions in
the C-terminal half of the Gla domain: APC(PT28/30), (Œ); APC(PT33–39), (‚);
APC(PT35/36), (); APC(PT36/38/39), (); APC(PT42/44/45), (f). Values corre-
spond to the mean of at least two determinations.
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5A, top panel). At the highest APC concentration tested (7 nM),
the ETPwas reduced to 15 1%of the ETPdeterminedwith no
APC present (Fig. 5, A and C). However, when a polyclonal
anti-protein S antibody known to inhibit APC-dependent pro-
tein S cofactor function (36) was incubated with 7 nMwild-type
APC, the ETP was not diminished and the anticoagulant effect
of wild-type APC was effectively lost (Fig. 5B). In this way, the
assay was shown to be completely dependent upon protein S to
facilitate APC down-regulation of thrombin generation. Vari-
ants APC(PT33–39), APC(PT35/36), and APC(PT36/38/39)
were tested in both the presence and absence of the inhibitory
anti-protein S antibody. In the presence of the anti-protein S
antibody, minimal ETP reduction (10%) was observed for
each of the APC variants tested (data not shown). In the
absence of the anti-protein S antibody, APC(PT35/36) reduced
thrombin generation 2-fold less effectively than wild-type
APC (Fig. 5,A andC). VariantsAPC(PT33–39) andAPC(PT36/
38/39) failed to inhibit thrombin generation at any of the APC
concentrations tested (Fig. 5, A and C), highlighting their
inability to interact with protein S to reduce thrombin genera-
tion. The phospholipid PE has been previously shown to signif-
icantly enhance APC anticoagulant activity (18). To confirm
that the results observed for variants APC(PT33–39),
APC(PT35/36), andAPC(PT36/38/39)were not a consequence
of defective interaction with PE, the same experiments were
performed in the presence of phospholipid vesicles composed
of PC/PS only. The results of these experiments were found to
replicate those performed in the presence of PC/PS/PE (data
not shown). These data confirm that APCGla domain residues
between 33–39 (and 36–39 in particular) are critical in medi-
ating protein S cofactor activity.
EPCR Recognition by Protein C Is Mediated by Leu-8—Using
surface plasmon resonance, human prothrombinwas tested for
sEPCR binding and was found to have essentially no sEPCR
affinity (Fig. 6A). Wild-type protein C bound sEPCR with high
affinity (Kd  117  36 nM) as reported previously (32) (Fig.
6A). Each protein C variant was tested for sEPCR binding using
a range of protein C concentrations (12.5–200 nM). The vast
majority of protein C variants exhibited sEPCR binding affinity
similar to that of wild-type protein C (data not shown). How-
ever, the protein C variant PC(PT8/10) (L8V/H10K) showed no
EPCR affinity, eliciting minimal response upon passing the
sEPCR surface (Fig. 6A). No specific binding response was
FIGURE 5. APC variants APC(PT33–39) and APC(PT36/38/39) have no pro-
teinS-dependentanticoagulant activity inproteinC-deficientplasma.A,
7 nM APC, (E); 3.5 nM APC (), or HEPES buffer (no APC), (‚) was incubated
with the protein C-deficient plasma. Thrombin generation in protein C-defi-
cient plasma was initiated by 16 pM tissue factor, 17.5 M phospholipid vesi-
cles (PC/PS/PE, 60%:20%:20%), 16.7mMCaCl2, andCTI (42g/ml).B, thrombin
generation in protein C-deficient plasma in thepresence of an inhibitory anti-
protein S polyclonal antibody (240 g/ml) with 7 nM APC (f) and in the
absence of APC (‚). C, the ETP for each variant in the presence of 7 nM APC
(white), 3.5 nM APC (gray), and with APC absent (black) was determined using
Thrombinoscope software. For each sample, the anticoagulant effect in the
presence of the inhibitory anti-protein S antibody (10%) has been sub-
tracted. Values correspond to the mean and S.E. of at least three
determinations.
FIGURE6.Leu-8 is required for sEPCRbinding.RecombinantproteinCaffin-
ity for sEPCR was assessed by surface plasmon resonance (see “Experimental
Procedures”). A, an anti-EPCR monoclonal antibody was immobilized onto
both flow cells of a CM5 sensor chip. sEPCR (800–900 RU) was then bound to
the second flow cell, the other flow cell acting as a “no sEPCR” control for
nonspecific binding. sEPCR binding of wild-type recombinant protein C (1),
PC(PT10) (2), PC(PT8) (3), PC(PT8/10) (4), and human plasma-purified pro-
thrombin (5) (all 80 nM) was assessed. B, 100 nM human protein C (1) and
human FVIIa (2) were assessed for sEPCR binding as above.
FIGURE 4. Protein CGla domain residues 33–39 are important for protein
S cofactor activity. Human protein S (3.25–25 nM) was incubated with APC
(0.2 nM), 2 nM FVa, and phospholipids (PC/PE/PS, 60%:20%:20%; 19 M) for 2
min and then added to a prothrombinasemixture (FXa, 0.1 nM; prothrombin,
0.5 M; phospholipids (as above, 25 M)) to assess FVa cofactor activity as
described under “Experimental Procedures.” Wild-type APC () in both pan-
els.A, APCvariantswith substitutions in theN-terminal half of theGladomain:
APC(PT3), (); APC(PT8/10), (E); APC(PT11/12), F; APC(PT18), (). B, APC vari-
antswith substitutions in theC-terminal half of theGla domain:APC(PT28/30),
(Œ); APC(PT33–39), (‚); APC(PT35/36), (); APC(PT36/38/39), (); APC(PT42/44/
45), (f). Values correspond to the mean and S.E. of at least three
determinations.
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observed even at high concentrations (up to 1.5 M) (data not
shown). To determine the relative contributions of residues
Leu-8 and His-10 in mediating ligand recognition, individual
variants containing either L8VorH10K substitutionswere gen-
erated and tested in the same manner. Although variant
PC(PT10) (H10K) bound sEPCRwith similar affinity (85 nM) to
wild-type protein C, no sEPCR binding was observed with
PC(PT8) (L8V), highlighting the critical nature of this residue in
EPCR recognition by protein C (Fig. 6A).
Sequence alignment of human vitamin K-dependent coagu-
lation protein Gla domains indicated that the protein C/APC
Gla domain -loop residues required for EPCR binding are
entirely conserved in FVII(a). FVIIa binding to sEPCR was
examined by surface plasmon resonance. FVIIa concentrations
between 12.5–200 nM were passed over an sEPCR surface, and
binding was assessed. FVIIa was found to bind sEPCR with
comparable affinity to protein C (150 nM) (Fig. 6B), confirm-
ing the importance of Leu-8 for EPCR recognition.
DISCUSSION
Using recombinant protein C/APC Gla domain variants, we
have elucidated the role of protein C/APCGla domain residues
inmediating protein S cofactor function andEPCR recognition.
13 recombinant protein C/APC variants were generated in
which the 22-protein C Gla domain residues not shared with
prothrombin were substituted with those of prothrombin (Fig.
1). This approach was used to enable Gla domain structure to
be maintained while probing protein C-specific interactions.
Themajority of variantswere expressed normally and exhibited
normal phospholipid binding (Fig. 2) and amidolytic activity
once activated.
Despite numerous studies describing the important protein S
domains/residues for protein S cofactor functionwithAPC (22,
26, 28, 37), the mapping of APC residues involved in mediating
the interaction with protein S has been limited. One study,
however, broadly implicated residues 22–45 of the APC Gla
domain in enabling protein S to act as an APC cofactor (18).
Using variants with substitutions within this region, we have
mapped the residues responsible formediating protein S cofac-
tor function upon APC. APC variants containing prothrombin
substitutions at positions 33, 34, 35, 36, 38, and 39 were not
effectively stimulated by protein S in anticoagulant assays,
highlighting the critical importance of this small cluster of APC
residues in defining protein S cofactor activity (Figs. 4 and 5).
APC variants containing substitutions in this region exhibited
normal FVa proteolysis in the absence of protein S (Fig. 3),
demonstrating that the loss of cofactor activity exhibited in the
presence of protein Swas not caused by disruption of any site of
FVa interaction within the APC Gla domain. Most of the resi-
dues in this region are either hydrophobic or acidic in nature
and are surface exposed on a model of the complete protein C
Gla domain with Ca2 bound (Fig. 7A) (38, 39). Consequently,
several of these residues form part of a putative protein-protein
binding site predicted using molecular modeling based on sur-
face hydrophobicity (40).
APC variants APC(PT35/36) and APC(PT36/38/39) pro-
vided a useful insight into the relative importance of some of
these residues in mediating protein S stimulation of APC anti-
FIGURE 7. Position of APC Gla domain residues critical for protein S
enhancement of APC activity and EPCR recognition. A, residues 33–39
(green, in stick representation within blue box) appear largely surface exposed
on a model of the full protein C Gla domain with Ca2 ions (red spheres)
coordinated by Gla residues (purple, stick representation) (38). Side chains of
residues 33–39 are colored by atom: carbon (green), oxygen (red ), and nitro-
gen (blue). Leu-8, important for EPCR recognition (see “Results”), is highlighted
on the -loop (green, Corey-Pauling-Koltun representation). B, the protein C
Gla domain (green) binds to sEPCR (gray) primarily via hydrophobic residues
(green) in the-loopwhenCa2 (red spheres) is boundbyGla residues (purple)
(30). C, Phe-4 and Leu-8 (yellow arrow) of protein C are primarily responsible
for binding and become buried in the sEPCR surface. D, PC(PT8) binding to
sEPCR is impaired by the inability of Val-8 (yellow arrow) to make full hydro-
phobic contacts with Leu-82 of sEPCR.
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coagulant activity. Residues Asp-36, Leu-38, and Ala-39 appear
critical in mediating protein S cofactor function, given the
inability of protein S to enhance APC(PT36/38/39) activity
(Figs. 4 and 5), despite normal phospholipid binding (Fig. 2) and
FVa proteolytic activity in the absence of protein S (Fig. 3).
Furthermore, the reduced sensitivity to protein S stimulation
exhibited by APC(PT35/36) (Figs. 4 and 5) highlights the
importance of one or both of acidic residuesAsp-35 andAsp-36
in enabling protein S enhancement of APC activity.
Our findings suggest surface residues in positions 33–39 of
APC determine protein S cofactor activity, most likely via a
direct binding interaction through these residues. Interestingly,
a cluster of 9 protein S Gla domain residues has recently been
identified that are crucial in mediating protein S cofactor activ-
ity, despite having no influence upon normal protein S phos-
pholipid binding (28). These residues (at positions 21, 23, 24,
28, 33, 34, 35, 41, and 45) are situated toward the C-terminal
end of the protein S Gla domain and are predicted to be surface
exposed. Furthermore, the majority of these residues possess
either hydrophobic or basic properties. Such protein S Gla
domain residues may offer a complementary binding site for
APC residues 33–39. However, direct binding between APC
and protein S has been difficult to demonstrate. A single report
using fluorescence-activated cell sorter analysis determined a
Kd of 75 nM between APC and protein S in the presence of
phospholipids (18). Further studies are now required to estab-
lish the precise role of individual APC residues in binding to
protein S.
EPCR binding by protein C/APC has been reported to be
specific to the protein C Gla domain (29). The majority of vita-
min K-dependent proteins are unable to bind to EPCR (31).3
From the crystal structure, it appears that only 5 protein C Gla
domain residues mediate EPCR binding. Of these, 3 are Gla
residues that are entirely conserved across all other vitamin
K-dependent coagulation proteins (Gla-7, Gla-25, and Gla-29).
The remaining residues (Phe-4 andLeu-8) are hydrophobic and
are predicted to contribute the majority of the binding energy
required for the protein C/APC-EPCR interaction (30). These
residues formpart of a hydrophobic-loop structure present in
all vitamin K-dependent coagulation proteins and important in
mediating phospholipid binding (41, 42). Prothrombin, like
protein C/APC, also possesses 4/5 EPCR binding residues,
including Phe-4 in its -loop, yet still cannot bind EPCR (29).
Consequently, we investigated whether specific structural
motifs within the protein C Gla domain were responsible for
defining protein C/APC specificity for EPCR or whether the
subtle residue differences between the protein C/APC -loop
and that of other vitamin K-dependent coagulation proteins
were sufficient to prevent EPCR binding.
Themajority of the proteinC variants tested bound to sEPCR
with similar affinity as wild-type protein C, excluding the pos-
sibility of protein CGla domain-specific structuralmotifs distal
from the EPCR binding residues influencing EPCR binding
specificity. However, protein C variants containing the L8V
substitution were completely unable to bind to sEPCR (Fig. 6),
highlighting the importance of Leu-8 in enabling EPCR recog-
nition and subsequent high affinity binding. Molecular model-
ing of PC(PT8) binding to sEPCR using the protein C/sEPCR
crystal structure provides a potential explanation for the loss of
EPCR binding in this variant (Fig. 7, B–D). When wild-type
protein C binds EPCR, Leu-8 of the protein C/APC -loop
makes close hydrophobic contacts with Leu-82 of sEPCR and
becomes buried in the EPCR surface (Fig. 7C). Modeling of the
PC(PT8) variant suggests that the shorter valine R group is
unable to contact Leu-82 of EPCR (Fig. 7D). Consequently,
despite retaining a similarly hydrophobic residue at position 8,
PC(PT8) and prothrombin are unable to bind EPCR.
Sequence alignment of the human protein C Gla domain
with that of other species indicates that Leu-8 is conserved in
the bovine sequence but not in rat and mouse, which have a
valine and methionine, respectively, at this position. EPCR res-
idues that directly contribute to protein C binding are com-
pletely conserved across human, bovine, rat, and mouse (43).
Human and bovine protein C bind to human sEPCRwith equal
affinity.3 Our study has shown that Val-8 in the -loop cannot
sustain human sEPCR binding (Fig. 6) and Met-8 in murine
protein C possesses an identical -loop to that of human FX,
which has been shown in binding competition experiments (31)
to exhibit minimal affinity for human EPCR. It seems likely that
small EPCR sequence variations close to the protein C/APC
binding residues on EPCR must alter the binding surface to
accommodate protein C/APC binding in these species.
The identical FVII(a)-loop sequence to protein C/APC has
been shown to contribute to the low phospholipid affinity of
both proteins in comparison to other vitamin K-dependent
proteins (17). Our data show that the functional similarity of
the Gla domains of protein C/APC and FVII(a) extends further,
as FVII(a) binds sEPCR with comparable affinity to protein
C/APC (117 and 150 nM, respectively; Fig. 6B). The physiolog-
ical consequences of FVII(a) ability to bind EPCR are uncertain.
FVII circulates in plasma at a 6-fold lower concentration than
proteinC,making it unlikely that FVII(a)would be able to effec-
tively compete with protein C/APC for EPCR binding under
normal physiological conditions. However, under conditions
where FVII(a) is elevated or administered therapeutically,
FVIIa antigen levels may more closely approach those of pro-
tein C, making competition for EPCR binding a possibility.
This report further demonstrates that the function of theGla
domain is not restricted to phospholipid binding. Selective
mutation has enabled the development of a compactmultifunc-
tional domain that interacts directly with a receptor (EPCR)
and a cofactor (protein S). The protein C Gla domain therefore
represents a paradigm for adaptive interactions of other Gla
domains.
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